New defense tested for transplant patients at risk of dangerous virus
NCT ID NCT07096453
Summary
This study is testing if a medication called CMVIG can prevent CMV infection in kidney transplant patients who are switching to a different anti-rejection drug called belatacept. Researchers will track how the body processes CMVIG and measure antibody levels over time in 30 adult participants. The goal is to see if this approach safely protects patients from a serious viral infection after transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CMV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Minnesota
RECRUITINGMinneapolis, Minnesota, 55455, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.